188 related articles for article (PubMed ID: 32086691)
1. The Dual-Targeting Activity of the Metabolite Substrate of Para-amino Salicyclic Acid in the Mycobacterial Folate Pathway: Atomistic and Structural Perspectives.
Agoni C; Ramharack P; Salifu EY; Soliman MES
Protein J; 2020 Apr; 39(2):106-117. PubMed ID: 32086691
[TBL] [Abstract][Full Text] [Related]
2. Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.
Hajian B; Scocchera E; Shoen C; Krucinska J; Viswanathan K; G-Dayanandan N; Erlandsen H; Estrada A; Mikušová K; Korduláková J; Cynamon M; Wright D
Cell Chem Biol; 2019 Jun; 26(6):781-791.e6. PubMed ID: 30930162
[TBL] [Abstract][Full Text] [Related]
3. Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.
Cheng YS; Sacchettini JC
Biochemistry; 2016 Feb; 55(7):1107-19. PubMed ID: 26848874
[TBL] [Abstract][Full Text] [Related]
4. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.
Zheng J; Rubin EJ; Bifani P; Mathys V; Lim V; Au M; Jang J; Nam J; Dick T; Walker JR; Pethe K; Camacho LR
J Biol Chem; 2013 Aug; 288(32):23447-56. PubMed ID: 23779105
[TBL] [Abstract][Full Text] [Related]
5. In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
Kumar M; Vijayakrishnan R; Subba Rao G
Mol Divers; 2010 Aug; 14(3):595-604. PubMed ID: 19697148
[TBL] [Abstract][Full Text] [Related]
6. Potency boost of a
Aragaw WW; Lee BM; Yang X; Zimmerman MD; Gengenbacher M; Dartois V; Chui WK; Jackson CJ; Dick T
Proc Natl Acad Sci U S A; 2021 Jun; 118(25):. PubMed ID: 34161270
[TBL] [Abstract][Full Text] [Related]
7. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG
Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
Li R; Sirawaraporn R; Chitnumsub P; Sirawaraporn W; Wooden J; Athappilly F; Turley S; Hol WG
J Mol Biol; 2000 Jan; 295(2):307-23. PubMed ID: 10623528
[TBL] [Abstract][Full Text] [Related]
9. Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Kumar VP; Cisneros JA; Frey KM; Castellanos-Gonzalez A; Wang Y; Gangjee A; White AC; Jorgensen WL; Anderson KS
Bioorg Med Chem Lett; 2014 Sep; 24(17):4158-61. PubMed ID: 25127103
[TBL] [Abstract][Full Text] [Related]
10. Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis.
Hajian B; Scocchera E; Keshipeddy S; G-Dayanandan N; Shoen C; Krucinska J; Reeve S; Cynamon M; Anderson AC; Wright DL
PLoS One; 2016; 11(8):e0161740. PubMed ID: 27580226
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
El-Hamamsy MH; Smith AW; Thompson AS; Threadgill MD
Bioorg Med Chem; 2007 Jul; 15(13):4552-76. PubMed ID: 17451962
[TBL] [Abstract][Full Text] [Related]
12. Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases.
da Cunha EF; de Castro Ramalho T; Bicca de Alencastro R; Maia ER
J Biomol Struct Dyn; 2004 Oct; 22(2):119-30. PubMed ID: 15317473
[TBL] [Abstract][Full Text] [Related]
13. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate.
Senkovich O; Schormann N; Chattopadhyay D
Acta Crystallogr D Biol Crystallogr; 2009 Jul; 65(Pt 7):704-16. PubMed ID: 19564691
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
Sharma K; Neshat N; Sharma S; Giri N; Srivastava A; Almalki F; Saifullah K; Alam MM; Shaquiquzzaman M; Akhter M
Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900287. PubMed ID: 31867798
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, molecular docking study and biological evaluation of new pyrrole scaffolds as potential antitubercular agents for dual targeting of enoyl ACP reductase and dihydrofolate reductase.
Mahnashi MH; Avunoori S; Gopi S; Shaikh IA; Saif A; Bantun F; Faidah HS; Alhadi AA; Alshehri JH; Alharbi AA; S R PK; Joshi SD
PLoS One; 2024; 19(5):e0303173. PubMed ID: 38739587
[TBL] [Abstract][Full Text] [Related]
16. Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors.
Panecka-Hofman J; Pöhner I; Spyrakis F; Zeppelin T; Di Pisa F; Dello Iacono L; Bonucci A; Quotadamo A; Venturelli A; Mangani S; Costi MP; Wade RC
Biochim Biophys Acta Gen Subj; 2017 Dec; 1861(12):3215-3230. PubMed ID: 28939533
[TBL] [Abstract][Full Text] [Related]
17. An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes.
Arooj M; Sakkiah S; Cao Gp; Lee KW
PLoS One; 2013; 8(4):e60470. PubMed ID: 23577115
[TBL] [Abstract][Full Text] [Related]
18. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis.
Chakraborty S; Gruber T; Barry CE; Boshoff HI; Rhee KY
Science; 2013 Jan; 339(6115):88-91. PubMed ID: 23118010
[TBL] [Abstract][Full Text] [Related]
19. Anticancer antifolates: current status and future directions.
McGuire JJ
Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544
[TBL] [Abstract][Full Text] [Related]
20. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria.
Rengarajan J; Sassetti CM; Naroditskaya V; Sloutsky A; Bloom BR; Rubin EJ
Mol Microbiol; 2004 Jul; 53(1):275-82. PubMed ID: 15225321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
